California’sOffice of Health Hazard Assessment (OEHHA) has scheduled this year’s meeting of the Developmental and Reproductive Toxicant Identification Committee (DARTIC) On December 11, 2019.
Reproductive Toxicant Identification Committee (DART-IC). At that meeting, the DART-IC will determine whether to identify the following cannabis-related substances as reproductive toxicants under Proposition 65: cannabis (marijuana), cannabis smoke (marijuana smoke), cannabis extracts, and Δ-9-Tetrahydrocannabinol (THC).
OEHHA issued a data call-in request on these substances on March 15, 2019. Many comments were submitted, some of which requested that the DARTIC review be clear about what, exactly, is being considered for listing. For example, the Personal Care Products Council, a trade association opined that “cannabis extracts” is too broad a term, and requested that OEHHA clarify that it does not include hemp or hemp-derived extracts. The law firm Keller & Heckman similarly expressed concern about the overbroad term “cannabis extracts,” observing:
Based on our research, it is clear “cannabis extracts” do not refer to a single commodity or mixture and—with the exception of the most abundant cannabinoid compounds (THC and CBD)—there are limited safety data on most “cannabis extracts.” [Citation omitted.] What data are available in the public literature that assess the developmental or reproductive toxicity of cannabis focuses almost entirely on THC and CBD. [Citation omitted.] Thus, we respectfully submit that the categorical listing of “cannabis extracts” would be inappropriate in that it would capture thousands of cannabis extracts that have no evidence of any reproductive toxicity concern.
Certainly, little is served by overbroad Proposition 65 chemical listings; they can lead to unnecessary warnings and can numb consumers to warnings, in general, the law firm asserted.
Although the data call-in period has closed, the DARTIC meeting will be open to the public and interested parties may provide limited oral comments to the expert panel.
It remains to be seen whether the vague and ambiguous language used to describe cannabinoid compounds will bring any clarity about the potential hazards that may be present in certain cannabinoid compounds.
The DART-I-C meeting will be webcast for those who cannot attend in person.